Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-07

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD). In particular, we will combine genetics, epigenetics, microbiome, immune response data together with anamnesis, questionnaires, electroencephalography (EEG) collected from subjects suffering MDD. Eventually, an Artificial Intelligence (AI)/Machine Learning (ML) predictive tool will be created to guide clinicians in improving MDD treatment and patient's stratification.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)

NCT05537558

Major Depressive Disorder

UNKNOWN

Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression

NCT06396312

Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms) Depressive Disorder, Major, Recurrent, With Psychotic Symptoms +4 more

RECRUITING

Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.

NCT04518592

Major Depressive Disorder

RECRUITING

Improving Health Care in Major Depressive Disorder

NCT05816018

Major Depressive Disorder

UNKNOWN

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

NCT02330679

Major Depressive Disorder

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Three hundred and fifty patients diagnosed with MDD will be enrolled for 24 months and divided into 4 groups according to age: 14-17 years (70 pediatric patients), 18-30 years (100 adult patients), 31-39 years (90 adult patients), 40-50 years (90 adult patients).

The study protocol includes 6 follow-up visits: T0 (enrollment), T1, T2, T3, T4, and T5. At each medical visit, psychometric questionnaires will be administered to the patients and contextual biological samples including blood, stool and saliva will be collected. The study will use a multi-omics approach including: metagenomic sequencing to characterize the microbiome composition; metabolomics to detect circulating metabolites; transcriptomics to quantify microRNAs; epigenomics to assess methylation variability between and within groups and immune assays to analyze the antibody immune response and inflammatory profiles (cytokines, interleukins and growth factors). Cortisol and lipoproteins will also be quantified. In parallel, cognitive assessment and emotional status will be recorded remotely by each patient via chatbot and wearable EEG devices, respectively. Specifically, the chatbot will collect patient's conversations and monitoring her/his feelings; the chat conversation will be than transformed in a machine-readable data. The EEG device is a mobile app that will also allows to associate brainwaves with patients' feelings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric patients affected by MDD

14-17 years (70 pediatric patients)

No interventions assigned to this group

Group 1 of adult patients affected by MDD

18-30 years (100 adult patients)

No interventions assigned to this group

Group 2 of adult patients affected by MDD

31-39 years (90 adult patients)

No interventions assigned to this group

Group 3 of adult patients affected by MDD

40-50 years (90 adult patients)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with Major Depressive Disorder as certified by a SCID 5 (Structured Clinical Interview for DSM-5) for DSM-S for adults and K-SADS-PL-DSM 5 (Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime for DSM 5) for adolescents.
* Currently experiencing a major depressive episode with a HAM-D (Hamilton Depression) score of 18 or greater, or alternatively, a MADRS (Montgomery-Asberg Depression Rating Scale) score of 18 or greater.
* About to start a new antidepressant.
* Not concurrently starting a new psychotropic medication.
* Age 14-50 years.
* Able to use mobile devices (smart phone, tablet).
* Willingness to provide written informed consent to participate.

Exclusion Criteria

* Intellectual disability.
* Neurological disease (multiple sclerosis, severe neurocognitive disorder, epilepsy).
* Current psychotic disorder or mood disorder with psychotic features.
* Primary diagnosis of alcohol or substance use disorder (DSM-5).
* Patients who started concomitant psychotropic medications less than one week ago.
* Active, ongoing inflammatory diseases (such as rheumatoid arthritis and rheumatic polymyalgia). or severe and unstable physical illness (such as recent myocardial infarction).
* A history of hepatitis B or C, human immunodeficiency virus, or evidence of active tuberculosis infection or any active systemic infection within 2 weeks prior to the start of the study.
* Use of antibiotics or other medications that may have affected the composition of the microbiota during the 30 days prior to baseline.
* Pregnancy and lactation.

Minimum Eligible Age

14 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No